HomeUSARegeneron Ventures Launches with $500M to Accelerate Biotech Innovation

Regeneron Ventures Launches with $500M to Accelerate Biotech Innovation

Regeneron Ventures, a Greenwich, Conn.-based biotech focused venture capital firm, announced its launch.

Regeneron Pharmaceuticals is the fund’s exclusive limited partner and has committed $100m annually for five years.

The firm aims to focus on investing in promising biopharmaceutical, health care and health technology companies.

The fund’s general partner will be independently managed by former Regeneron Pharmaceuticals executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who together will lead investment strategy of the fund. Drs. Markowitz and Aberman both started their professional careers in medicine before transitioning into investing and operational roles in biotech.

Prior to joining Regeneron Ventures, Michael Aberman, M.D., was the CEO and Co-founder of XenImmune Therapeutics, a seed stage biotech company. Previously, he was the president and chief executive officer of Quentis Therapeutics, an early-stage biotech company. Before Quentis, Aberman spent over seven years at Regeneron, most recently as the Senior Vice President of Investor Relations and Strategy. In that role, he was a member of the senior management team and responsible for investor relations, corporate communications, business development, and corporate strategy. Aberman joined Regeneron after six years as a biotechnology analyst at Credit Suisse and Morgan Stanley. Previously, he was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Aberman received his B.A. from Cornell University, his medical degree from the University of Toronto, completed residency training in internal medicine at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business.

Jay Markowitz, M.D., joined Regeneron Ventures from ARCH Venture Partners, where he was a Senior Partner. In his three years at ARCH, Markowitz was a founder of three companies and served as a board member and advisor for two others. He has 16 years of public market investment experience at T. Rowe Price Associates and Capital World Investors, where he focused on the biotechnology and pharmaceutical industry. From 2017 to 2020, Markowitz was a Senior Vice President at Regeneron. Prior to his investment career, Jay was a transplant surgeon and assistant professor at the Johns Hopkins University School of Medicine. He completed a transplant surgery fellowship at UCLA, a general surgery residency at the Massachusetts General Hospital, and a research fellowship in cellular and molecular immunology in the division of cancer biology at the Harvard School of Public Health. Markowitz received his M.D. from Duke University, where he was elected to the Alpha Omega Alpha honor society, and his B.A. in chemistry, Summa Cum Laude, from Columbia University, where he was elected to Phi Beta Kappa. 

VCWire

16/04/2024